Company / Free Cash Flow
Mereo BioPharma Group plc Free Cash Flow History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$31.0M
FY2025
5-year range
-$32.8M / -$21.1M
FY2023-FY2025
Trend
+5.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$21M to -$31M over the past 2 years.
Based on SEC 10-K filings.
-$31M in FY2025.
Declined from -$21M to -$31M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 5.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score -7.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$31.0M | +5.6% |
| FY2024 | -$32.8M | -55.4% |
| FY2023 | -$21.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 27, 2026